Latest neurofibromatosis Stories
- Funding supports continued focus on rare disorders - SOUTH PLAINFIELD, N.J., June 15 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the receipt of two government grants to support clinical development programs in rare disorders. The U.S.
Rice University researchers have found a potential clue to the roots of epilepsy, autism, schizophrenia and other neurological disorders.
By Tischler, Arthur S * Context.-Advances in genetics and gene expression profiling have led to new ways of thinking about the pathobiology of pheochromocytoma and extra-adrenal paraganglioma.
U.S. medical scientists say they have discovered a mutation that causes a childhood tumor syndrome also impairs growth hormone secretion.
By Faye Flam, The Philadelphia Inquirer Jul. 6--By completely reversing four types of mental impairment in mice, scientists are overturning the long-entrenched notion that our mental capacity is hardwired and immutable.
By Rodriguez, Fausto J Perry, Arie; Gutmann, David H; O'Neill, Brian Patrick; Leonard, Jeffrey; Bryant, Sandra; Giannini, Caterina Abstract There are few pathologic studies of gliomas in patients with neurofibromatosis type 1.
In a surprise twist that recalls the film classic "Flowers for Algernon," but adds a happy ending, UCLA scientists used statins, a popular class of cholesterol drugs, to reverse the attention deficits linked to the leading genetic cause of learning disabilities. The Nov. 8 issue of Current Biology reports the findings, which were studied in mice bred to develop the disease, called neurofibromatosis 1 (NF1).
This week, researchers report evidence that a statin drug already shown to be safe for use in humans has proven effective at correcting cell-cell communication and curing learning disfunction in a mouse model of Neurofibromatosis type I, a human genetic disorder that causes learning disabilities in millions of people worldwide.
Researchers studying a mouse model of neurofibromatosis 1 (NF1), a genetic condition that causes childhood brain tumors, have found their second new drug target in a year, a protein called methionine aminopeptidase-2 (MetAP2).